Combination of | |
---|---|
Dolutegravir | HIV integrase strand transfer inhibitor (INSTI) |
Rilpivirine | HIV non-nucleoside reverse-transcriptase inhibitor (NNRTI) |
Clinical data | |
Trade names | Juluca |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Dolutegravir/rilpivirine, sold under the brand name Juluca, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. [9] [7] It contains the medicines dolutegravir and rilpivirine. [7] It is taken by mouth. [7]
The most common adverse reactions (of all severity grades) are diarrhea and headache. [7]
Dolutegravir/rilpivirine was approved for use in the United States in November 2017, [7] [10] [11] and for use in the European Union in May 2018. [8]
Dolutegravir/rilpivirine is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. [8]